Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
VistaGen Therapeutics, Inc. (OP: VSTA)
0.7001 USD  -0.0999 (-12.49%)
Streaming Delayed Price  /  Updated: 9:30 AM EDT, May 21, 2013  /  Add to My Watchlist      
View: Quote News Research
All news about VistaGen Therapeutics, Inc.
 
VistaGen Therapeutics (VSTA) and Duke University Report Positive Results on Production of Functional 3D Human Heart Tissue
May 08, 2013
from Latest Press Releases
Enhancing its Mojo – financings spice the printed page.
May 07, 2013
The 6 W’s: Who, what, where, when, why and what of it RegMed sector has another wave of fulfilled and anticipated financings which should … broadcast the viability of the sector – as investors are... Read More
category Henry McCusker
from Bio-Wire.Com
VistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue
May 07, 2013
Living Heart Muscle Derived From Human Stem Cells Is Closest Man-Made Approximation of Natural Human Heart Muscle to Date Read More
from Marketwired News Releases
The Early Movers – who’s hot, who’s not
April 19, 2013
Which RegMed companies are making moves in the 1st hourSigns of life … Mesoblast ADR (PINK: MBLTY +$0.25) and Dendreon (DNDN +$0.16), are the leaders as today’s market opens… …followed by Verastem... Read More
category Henry McCusker
from Bio-Wire.Com
UPDATE: VistaGen Announces $36 Million Strategic Financing Agreement
April 10, 2013
Proceeds Will Accelerate Stem Cell Technology-Based Drug Rescue, Predictive Toxicology and Drug Metabolism Programs Read More
from Marketwired News Releases
RegMed Daily – The Early Movers
April 10, 2013
The 1st hour … which RegMed companies are making moves   Signs of life … VistaGen (PINK: VSTA +$0.117 and Verastem (NASDAQ: VSTM +$0.11) are the leaders as today’s market opens… …followed by ReNeuron... Read More
category Henry McCusker
from Bio-Wire.Com
VistaGen Therapeutics (VSTA) has $36 M Strategic Financing Agreement with BERGAMO
April 10, 2013
             For 72 M shares of restricted common stock   VSTA signed a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp., a global diversified investment holding... Read More
category Henry McCusker
from Bio-Wire.Com
VistaGen Announces $36 Million Strategic Financing Agreement
April 10, 2013
Proceeds Will Accelerate Stem Cell Technology-Based Drug Rescue, Predictive Toxicology and Drug Metabolism Programs Read More
from Marketwired News Releases
VistaGen Therapeutics to Present Enhancements and Expanded Validation of LiverSafe 3D(TM) at Society of Toxicology's 52nd Annual Meeting
March 12, 2013
from Marketwired News Releases
VistaGen Therapeutics to Present CardioSafe 3D(TM) Developments at Society of Toxicology's 52nd Annual Meeting
March 11, 2013
Poster Will Discuss Expanded and Improved Applications of Novel Pluripotent Stem-Based Screening System for Heart Toxicity Read More
from Marketwired News Releases
VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3D(TM)
March 04, 2013
Companies Structure Collaboration to Focus on Development and Characterization of VistaGen's Human Pluripotent Stem-Cell Derived Liver Cells Read More
from Marketwired News Releases
VistaGen's Collaborators Identify Definitive Precursor for Adult Blood and the Immune System
February 07, 2013
Latest Developments Enable Advanced Tools for Drug Rescue and Potential Cell Therapies Based on Human Definitive Hematopoietic Precursor Cells Read More
from Marketwired News Releases
Vistagen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101
January 23, 2013
Lead Prodrug Candidate Is Being Developed for Chronic Neuropathic Pain Read More
from Marketwired News Releases
VistaGen Therapeutics to Present at Noble Financial Capital Markets Ninth Annual Equity Conference
January 22, 2013
from Marketwired News Releases
VistaGen Therapeutics Becomes Member of Centre for Commercialization of Regenerative Medicine (CCRM) Consortium
December 03, 2012
from Marketwired News Releases
MissionIR Blog - VistaGen Therapeutics, Inc. (VSTA) Joins Centre for Commercialization of Regenerative Medicine (CCRM) Consortium
December 03, 2012
from Latest Press Releases
MissionIR Blog - VistaGen Therapeutics (VSTA) Focused on Preventing Some Very Costly Surprises
November 22, 2012
from Latest Press Releases
VistaGen Therapeutics Enhances Predictive Liver Toxicology and Drug Metabolism Bioassay System -- LiverSafe 3D(TM)
November 13, 2012
Novel Human Stem Cell-Based Bioassay Based on VistaGen's Human Clinical Trials in a Test Tube(TM) Platform Read More
from Marketwired News Releases
MissionIR Blog - VistaGen Therapeutics, Inc. (VSTA) Taps the Turnaround
November 13, 2012
from Latest Press Releases
MissionIR News - VistaGen Therapeutics Presents Heart Tissue Engineering Progress at American Heart Association 2012 Scientific Sessions
November 09, 2012
from PRWeb
VistaGen Therapeutics and Duke University Announce Heart Tissue Engineering Progress at American Heart Association 2012 Scientific Sessions
November 07, 2012
Joint Effort Combines Complementary Expertise at the Forefront of Cardiac Stem Cell Technology, Electrophysiology and Tissue Engineering Read More
from Marketwired News Releases
MissionIR News - VistaGen Therapeutics Secures $3.25 Million Financing and Completes $3.0 Million Debt Restructuring
October 17, 2012
from PRWeb
VistaGen Therapeutics Completes $3.25 Million Financing and $3.0 Million Debt Restructuring
October 16, 2012
Company Emerges With Substantially Improved Balance Sheet and Growth Capital Read More
from Marketwired News Releases
MissionIR News - VistaGen Therapeutics Secures Additional Financing from Largest Institutional Investor and Completes Long-term Debt Restructuring
September 07, 2012
from PRWeb
VistaGen Therapeutics, Inc. (VSTA) Secures Additional Financing from Largest Institutional Investor and Completes Long-term Debt Restructuring
September 07, 2012
from Latest Press Releases
VistaGen Therapeutics Announces Strategic Financing With Platinum Long Term Growth Fund
September 06, 2012
Company Also Completes Long-Term Debt Restructuring Read More
from Marketwired News Releases
VistaGen CEO Issues Update Letter to Stockholders
May 14, 2012
from Marketwired News Releases
VistaGen Secures Key U.S. Patent Covering Stem Cell Technology Methods Used to Test Drug Candidates for Liver Toxicity
April 25, 2012
from Marketwired News Releases
VistaGen Licenses Breakthrough Stem Cell Culture Technology to Speed Development of Drug Screening and Cell Therapy for Immune System Disorders
April 16, 2012
from Marketwired News Releases
VistaGen Therapeutics Enters Strategic Drug Screening Collaboration With Vala Sciences
March 21, 2012
Goal to Combine Human Stem Cell-Derived Cardiomyocytes With Novel High-Speed Kinetic Imaging Read More
from Marketwired News Releases
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here